ARIKACE® (Inhaled liposomal amikacin)
A Potential New Weapon in the Treatment of Serious Chronic Lung Infections
ARIKACE (liposomal amikacin for inhalation) is a differentiated, inhaled antibiotic engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for patients.
ARIKACE is administered once daily using an optimized eFlow® Electronic Nebulizer (PARI Pharma GmbH).*
ARIKACE is an inhaled antibiotic treatment for serious lung infections such as Pseudomonas and NTM. The key active ingredient, amikacin, is an FDA-approved antibiotic with proven efficacy in the treatment of a board range of gram-negative infections, including Pseudomonas and NTM. Amikacin is in the aminoglycoside class of antibiotics and is currently delivered intravenously.
Reference: Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR (2008) Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. Journal Antimicrob Chemother Apr;61(4):859-68.
Our proprietary liposomal delivery technology is engineered to deliver this proven and potent anti-infective directly to the site of serious lung infections and provides for potential improvements to the conventional inhalation methods of delivery drug to the pulmonary system.
*In the US and Canada, Investigational eFlow Nebulizer System (PARI Respiratory Equipment, Inc.).
References
1 Adapted from Cystic Fibrosis Foundation, Patient Registry Annual Data Reports, 2011.
2 Hoiby BMC Medicine, 2011 , 9:32.
3 Clarity Pharma Research, Patient Chart Study, 2012.
